Cover Image
市場調查報告書

Novogen Limited :產品平台分析

Novogen Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224651
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Novogen Limited :產品平台分析 Novogen Limited - Product Pipeline Review - 2015
出版日期: 2015年11月30日 內容資訊: 英文 28 Pages
簡介

Novogen Limited 是擁有二大藥劑開發平台的澳洲生物科技企業。即是以癌細胞骨骼為標的,治療黑色素瘤,前列腺癌、神經母細胞瘤等用的抗甲狀腺微粒體抗體,以及以癌細胞為標的,治療卵巢癌,神經膠母細胞瘤用的Super benzopyran(SBP)。

本報告提供Novogen Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Novogen Limited的基本資料

Novogen Limited概要

  • 主要資訊
  • 企業資料

Novogen Limited :R&D概要

  • 主要的治療範圍

Novogen Limited :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Novogen Limited :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Novogen Limited :藥物簡介

  • ATM-3507
  • TR-100
  • Trilexium
  • Trx-7
  • Small Molecules for CNS and Muscular Dystrophy Diseases

Novogen Limited :開發平台分析

  • 各分子類型

Novogen Limited :最近的開發平台趨勢

Novogen Limited :暫停中的計劃

Novogen Limited :企業發表

Novogen Limited :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07829CDB

Summary

Global Markets Direct's, 'Novogen Limited - Product Pipeline Review - 2015', provides an overview of the Novogen Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novogen Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Novogen Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Novogen Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Novogen Limited's pipeline products

Reasons to buy

  • Evaluate Novogen Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Novogen Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Novogen Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Novogen Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novogen Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Novogen Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Novogen Limited Snapshot
    • Novogen Limited Overview
    • Key Information
    • Key Facts
  • Novogen Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Novogen Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Novogen Limited - Pipeline Products Glance
    • Novogen Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Novogen Limited - Drug Profiles
    • ATM-3507
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TR-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Trilexium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRXE-0025
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for CNS and Muscular Dystrophy Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Novogen Limited - Pipeline Analysis
    • Novogen Limited - Pipeline Products by Route of Administration
    • Novogen Limited - Pipeline Products by Molecule Type
  • Novogen Limited - Recent Pipeline Updates
  • Novogen Limited - Dormant Projects
  • Novogen Limited - Company Statement
  • Novogen Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Novogen Limited, Key Information
  • Novogen Limited, Key Facts
  • Novogen Limited - Pipeline by Indication, 2015
  • Novogen Limited - Pipeline by Stage of Development, 2015
  • Novogen Limited - Monotherapy Products in Pipeline, 2015
  • Novogen Limited - Partnered Products in Pipeline, 2015
  • Novogen Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Novogen Limited - Preclinical, 2015
  • Novogen Limited - Discovery, 2015
  • Novogen Limited - Pipeline by Route of Administration, 2015
  • Novogen Limited - Pipeline by Molecule Type, 2015
  • Novogen Limited - Recent Pipeline Updates, 2015
  • Novogen Limited - Dormant Developmental Projects,2015
  • Novogen Limited, Subsidiaries

List of Figures

  • Novogen Limited - Pipeline by Top 10 Indication, 2015
  • Novogen Limited - Pipeline by Stage of Development, 2015
  • Novogen Limited - Monotherapy Products in Pipeline, 2015
  • Novogen Limited - Pipeline by Top 10 Molecule Type, 2015
Back to Top